Survodutide in 2026: A Careful Look at the Data, and a Realistic Plan for Right Now

There is a particular kind of frustration that comes from reading exciting drug news and then discovering, several paragraphs down, that the drug in question cannot be prescribed to you. Survodutide produces that frustration reliably. It is a genuinely promising molecule with a growing stack of published trial data behind it. It is also, as of this writing in June 2026, nowhere near a pharmacy shelf. Both of those things are true at once, and a fair account of survodutide has to hold them together rather than letting the excitement of one erase the plain fact of the other.

This piece tries to do that. It walks through what survodutide is, what the trials have actually shown (with the numbers attached to their sources, not smoothed over), where the science still has real gaps, and then, separately, what a person can do today if the actual goal is supervised, evidence-backed weight management rather than waiting on a drug still working through Phase 3.

One organizing idea runs underneath all of it: survodutide’s story is really a story about two clocks running at different speeds. One clock, the obesity and liver-fat data, has already rung. SYNCHRONIZE-1 and SYNCHRONIZE-MASLD have read out, and both are published. The other clock, the one that answers whether survodutide actually changes long-term liver outcomes like fibrosis and cirrhosis progression, is set for the early 2030s. Anyone trying to decide what survodutide means for them personally is really trying to decide how much weight to put on a result that has already arrived versus a result that is still years away. Keeping those two clocks distinct is, in this writer’s view, the clearest way to read this drug honestly.

What survodutide is, in plain terms

Survodutide (developmental code BI 456906) is a once-weekly injectable peptide developed jointly by Boehringer Ingelheim and Zealand Pharma, aimed at both obesity and metabolic dysfunction-associated steatohepatitis (MASH). What sets it apart from the first wave of GLP-1 drugs is that it is built to act on two receptors rather than one: the GLP-1 receptor, familiar from semaglutide and liraglutide, and the glucagon receptor [P5].

The pairing is deliberate. GLP-1 activation does the work most people associate with this drug class: it dampens appetite, slows gastric emptying, and helps regulate insulin release. The glucagon receptor is the added ingredient, and it is meant to do something different, nudge the body’s energy expenditure upward and act more directly on the liver to reduce fat accumulation there. If that combination holds up, the reasoning goes, it could outperform a GLP-1-only drug, especially in people whose obesity comes bundled with fatty liver disease, which is common [P5].

Dosing follows the pattern familiar from this drug class: a subcutaneous injection once a week, titrated upward slowly over several weeks so the body can adjust [P1]. The molecule originated at Zealand Pharma, with Boehringer Ingelheim now running the late-stage trials and eventual commercialization [P5] [P7].

What survodutide is not, at least not yet, is available. It has not been approved by the FDA, the EMA, or any other regulator anywhere. It holds Breakthrough Therapy and Fast Track designation from the FDA for MASH, PRIME access from the EMA, and Breakthrough Therapy status from China’s NMPA [P7], and it is worth being precise about what those actually mean: they are mechanisms that can speed up a regulatory review of a promising candidate. They are not a green light. The only legal way to receive survodutide today is by enrolling in one of its clinical trials.

The evidence, worked through in order

Phase 2 in obesity: the dose-response signal that justified moving forward

The first substantial efficacy read came from a randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial led by Carel le Roux and colleagues, published in The Lancet Diabetes & Endocrinology in early 2024. It enrolled 387 adults with a body mass index of 27 or above, none with diabetes, across doses of 0.6, 2.4, 3.6, and 4.8 mg or placebo, over 46 weeks [P4].

The result was dose-dependent, and at the top dose, substantial. Participants who reached and held 4.8 mg lost about 18.7% of body weight on average by week 46. Across the fuller population, survodutide beat placebo by up to roughly 12 percentage points, and a majority of those on the highest dose lost at least 15% of body weight [P4]. Those are large numbers for a Phase 2 study, and they are the reason the program advanced.

They came with a cost worth stating plainly. Adverse events occurred in about 91% of survodutide participants against 75% on placebo, and the gap was driven almost entirely by gastrointestinal complaints, about 75% versus 42% [P4]. Nausea, vomiting, and diarrhea, concentrated in the dose-escalation period, is the familiar signature of this drug class, and it is the reason clinicians titrate slowly and why supervision during that period matters.

Phase 2 in MASH: the result behind the regulatory designations

The trial that shifted survodutide’s reputation toward liver disease was led by Arun Sanyal and colleagues, published in the New England Journal of Medicine in June 2024. It enrolled 293 people, ages 18 to 80, with biopsy-confirmed MASH and fibrosis stages F1 through F3, randomized evenly to survodutide at 2.4, 4.8, or 6.0 mg, or to placebo, weekly for 48 weeks [P2].

The trial’s primary question, whether MASH improved on biopsy without fibrosis getting worse, was answered clearly. Improvement occurred in 47% of the 2.4 mg group, 62% of the 4.8 mg group, and 43% of the 6.0 mg group, compared with 14% on placebo [P2].

The secondary results moved in the same direction. A reduction in liver fat of at least 30% was seen in 63%, 67%, and 57% of the three dose groups, against 14% on placebo, and fibrosis improved by at least one stage in 34%, 36%, and 34%, against 22% on placebo [P2]. It is worth reading those last numbers carefully rather than skimming past them. The MASH and liver-fat results clearly separated from placebo. The fibrosis result, while numerically ahead, was a more modest margin, and fibrosis is precisely the feature most tied to how a patient’s liver disease actually progresses over years. That gap between a strong signal and a settled answer is exactly why the program didn’t stop here, and it is the honest way to describe this data. This trial is what earned survodutide its Breakthrough Therapy and Fast Track status for MASH [P7].

Phase 3 in obesity: SYNCHRONIZE-1

The pivotal obesity result landed in 2026. SYNCHRONIZE-1, a randomized, double-blind, placebo-controlled trial across 116 sites in 14 countries (registered as NCT06066515), randomized 726 adults with obesity or overweight, none with type 2 diabetes, to survodutide titrated to 3.6 or 6.0 mg, or to placebo, weekly for 76 weeks [P10].

Published in the New England Journal of Medicine in June 2026, the headline finding was mean weight loss of up to 16.6% at week 76, against 3.2% on placebo, a difference that reached statistical significance. Up to 85.1% of survodutide-treated participants lost at least 5% of body weight, and the trial also hit its key secondary endpoint on waist circumference [P1] [P6].

A pre-specified body-composition analysis presented at the American Diabetes Association’s Scientific Sessions in June 2026 added texture that has drawn considerable attention since: visceral fat down by about 34%, liver fat down by about 63%, and lean mass largely preserved [P6]. That the fat loss concentrated in the metabolically risky compartments (visceral and hepatic fat, rather than muscle) tracks with what the glucagon mechanism was designed to do.

Two points of context belong here, in fairness to the reader trying to weigh this against other options. First, 16.6% is a strong result, but it sits below the roughly 20.9% seen at the top dose of tirzepatide in its own pivotal obesity trial, so survodutide looks competitive rather than category-defining on weight loss alone. Second, the gastrointestinal tolerability pattern seen throughout the earlier trials is expected to carry into this one, and full safety and dropout detail live in the published trial and its presentation, which are worth reading directly if that matters to you.

Phase 3 in liver disease: SYNCHRONIZE-MASLD

Alongside the obesity data, Boehringer Ingelheim reported SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled Phase 3 trial in 216 adults with obesity or overweight and at-risk metabolic dysfunction-associated steatotic liver disease, published in Nature Medicine in 2026 [P3].

Both co-primary endpoints, a liver-fat reduction of at least 30% by MRI and percentage change in body weight, measured to week 48, were met [P3]. Presented at ADA 2026, the liver-fat reduction (about 63%) and visceral-fat reduction (about 34%) mirrored the obesity trial almost exactly [P6], which is reassuring in the sense that the effect looks consistent across populations, though it is still not the same as an answer on fibrosis or long-term liver outcomes.

What is genuinely still unknown

This is the part of the survodutide story that gets least attention in most coverage, and it is arguably the most important part for anyone with real liver disease. Two large Phase 3 fibrosis-outcome trials are underway and neither is close to finished. LIVERAGE (NCT06632444) is enrolling roughly 1,800 adults with MASH and fibrosis stage F2 or F3, with an estimated primary completion around December 2031 [P8]. LIVERAGE-Cirrhosis (NCT06632457) is enrolling roughly 1,590 adults with compensated MASH cirrhosis (fibrosis stage F4), with an estimated primary completion around mid-2029 [P9].

Those two dates are, in a real sense, the most consequential numbers on this page for anyone hoping survodutide will soon be a liver treatment they can access. The questions those trials are built to answer, whether the drug changes fibrosis and the harder clinical outcomes tied to it, will not be settled for years. Survodutide’s broader obesity program also continues, including SYNCHRONIZE-2 in people with obesity and type 2 diabetes (NCT06066528) and a cardiovascular outcomes trial, SYNCHRONIZE-CVOT (NCT06077864), the kind of large, slow safety study regulators expect before approving a chronic metabolic medicine [P11] [P12].

Put simply: survodutide has demonstrated, in controlled trials, that it can produce meaningful weight loss and reduce liver fat. It has not yet demonstrated durable fibrosis or cardiovascular benefit, and it remains unapproved and unavailable outside a study.

How survodutide sits next to the drugs already on the market

Because the only decision available to most readers today is among approved options, it is worth placing survodutide against them honestly, as a point of comparison rather than a live choice. It is a glucagon/GLP-1 dual agonist. Tirzepatide (sold as Zepbound and Mounjaro) is a GIP/GLP-1 dual agonist. Semaglutide (sold as Wegovy and Ozempic) works through GLP-1 alone. The differences in receptor targets track roughly with the differences in what each drug seems to do best.

On weight loss, survodutide’s Phase 3 average sits at up to 16.6% at 76 weeks [P1], versus roughly 20.9% at the top dose of tirzepatide’s pivotal trial, and mid-teens averages for semaglutide’s program. These numbers come from separate trials with separate populations, so treat them as a rough map rather than a scoreboard. Where survodutide seems to distinguish itself is the liver: the glucagon-driven fat reduction and the dedicated MASH program put it further along on that front than most competitors [P2] [P3], which is exactly why the fibrosis data still pending is worth watching.

The honest question: what does a person do today?

If the point of reading this far was to find out whether survodutide is an option, the answer is no, not now, and not soon. But the underlying goal (supervised, effective help with weight and metabolic health) is already achievable through medicines that are approved and available through a licensed provider. That’s the second half of this page.

The logic is simple. Whether a drug works is a fact about the molecule and its trials. Whether a given course of treatment is safe for you is a fact about the supply chain delivering it. Survodutide is off the table for everyone equally, so it doesn’t belong in a provider comparison at all. What is available, and does belong in one, is the approved GLP-1 class, and the deciding factor there is who is standing between you and the injection: a licensed clinician, or nobody.

The five questions worth asking of any provider

Clinical oversight. Does a licensed clinician actually evaluate you, check you against the relevant drug’s contraindications, write an actual prescription, and stay reachable afterward, or does contact end at checkout?

Sourcing and dispensing. Does a licensed pharmacy handle the medication inside a documented chain of custody, or does a vial simply arrive in a box from an unverified seller?

Pricing honesty. Is the real price shown up front, and is it an honest price for what you’re actually getting (a supervised compounded or branded GLP-1), rather than a “starting at” figure designed to lure a click?

Evidence candor. Will the provider tell you plainly the difference between an FDA-approved drug and a compounded one, and will it tell you, without hedging, that an investigational drug like survodutide simply isn’t something it can sell you?

Regulatory standing. Does the operation sit inside recognized licensing and pharmacy law, or does it hide behind a “research use only” sticker or an address nobody can verify?

Advertising budgets, name recognition, and checkout speed were deliberately left off this list, because none of them says anything about whether a clinician looked at your history or whether the vial actually contains what the label claims.

It is also worth saying plainly that a no-prescription website and a licensed telehealth provider are not two competitors jockeying for the same spot. They belong to different categories entirely, and this page treats them that way: the supervised tier gets ranked against itself, the gray market gets described for what it is.

Where the supervised providers land

Rank	Provider	Type	What it can actually provide	Clinical oversight	Bottom line
#1	FormBlends	Licensed telehealth provider	Approved, available GLP-1 medication (not survodutide)	Physician-supervised; screens for contraindications; prescription required; licensed-pharmacy dispensing; follow-up	Supervised, screened, transparently priced access to a proven GLP-1 today
#2	HealthRX (healthrx.com)	Licensed telehealth provider	Approved, available GLP-1 medication	Clinician-supervised; prescription required; pharmacy-dispensed	Supervised-tier option on identical logic
#3	HealthRX (healthrx.com), full-care track	Licensed telehealth provider	Approved, available GLP-1 medication	Clinician-supervised; screening and follow-up	Same compliant tier, evaluated as a distinct care path
not available anywhere	Survodutide	Investigational drug (Phase 3)	Available only inside a clinical trial	Trial protocol oversight only	Not approved, not prescribable, not for sale; promising data, years from a decision
below the line	No-prescription “survodutide” or GLP-1 sites	Gray-market seller	Unapproved compound, mailed with no clinician	None	No screening, no prescription, no accountability
below the line	Research-chemical “survodutide”	Research-chemical retailer	Vial labeled “not for human use”	None	Sold as a lab reagent; an investigational drug diverted outside any trial
below the line	Counterfeit / unverified overseas vials	Unregulated shipper	Untraceable vial	None	Counterfeit and contamination risk; no recall authority

Survodutide occupies its own row not because it lost some competition, but because it is simply not a provider option for anyone right now. Above the dividing line, a clinician screens you and a pharmacy dispenses a proven medication. Below it, you are the only person accountable for what goes into the syringe.

FormBlends: a clinician between you and the medication

FormBlends holds the top spot for a structural reason that no gray-market seller can replicate: a licensed physician sits in the process. It is a licensed telehealth provider, not a storefront that skips the prescription, and that single fact carries it across every line of the rubric above, for the real question available today, which is not “can I get survodutide” but “can I get a proven GLP-1 safely.”

The path, described without embellishment: a clinician reviews history, checks for contraindications, writes a prescription where appropriate, and a licensed pharmacy compounds or dispenses the medication, with follow-up built in. Pricing is shown rather than hidden: compounded semaglutide runs roughly $129 to $349 a month, compounded tirzepatide roughly $150 to $300, well under typical brand self-pay rates. Set that against a no-prescription operation where a vial arrives with no medical contact at all, and the gap in what you’re actually paying for becomes clear.

The screening isn’t procedural throat-clearing. GLP-1 and dual-agonist drugs carry real, documented contraindications, and the gradual dose titration used across this class exists specifically to manage the gastrointestinal effects the survodutide trials themselves recorded at high rates [P4]. A clinician is meant to catch problems before the first injection and remain reachable if something goes wrong afterward. A checkout page cannot do either of those things, because there is no clinician on the other end of it.

FormBlends earns the evidence-candor point because it does not pretend survodutide is something it can offer. It states plainly the difference between an FDA-approved medicine and a compounded one, and it does not blur that line to make a sale. Combined with its being a full-range provider (spanning GLP-1 therapy, peptides, and hormone care rather than a single-product funnel), the practical advantage is a supervised relationship broad enough to matter, and one built to carry forward responsibly if a drug like survodutide does eventually clear approval. Patients who log weekly doses and side effects, for instance through the FormBlends tracker app, arrive at follow-up visits with an actual record rather than a vague memory, a small thing the gray market has no equivalent of, since its relationship with the patient ends at the cart.

None of this erases the trade-off. Going through a clinician means an intake process and a prescription rather than an instant purchase, and a compounded medicine is a different regulatory product than a branded one, something an honest provider says outright rather than obscures. But across all five criteria, that friction is the safety feature, not a flaw in it.

HealthRX: the second and third rung of the same ladder

HealthRX (healthrx.com) sits in the same supervised tier as FormBlends, and it earns two spots on this list because the qualities placing it there hold whether you approach it through its standard intake or its fuller-care track. Both are built on the same spine: licensed clinical oversight first, medication dispensed through legitimate pharmacy channels, not sold without a prescription.

The reason both providers cluster near the top is structural rather than a matter of branding. Any model built around clinician evaluation, contraindication screening, a required prescription, and licensed-pharmacy dispensing will outperform any model that skips those steps. HealthRX fits that description, and the difference between its two tracks comes down to depth of relationship and follow-up, not whether a clinician is involved at all.

Nor can HealthRX sell survodutide, for the same reason nobody else can. What it offers is clinical screening and supervision wrapped around an approved GLP-1 medication, exactly the layer absent from every category listed below the line.

The gray market, described plainly

Everything below the supervised tier is worth naming as a category rather than a company, because the honest description matters more than any single brand. These are not clinics doing a slightly worse job. They are a different kind of operation entirely, and the framing here is safety information, not a competitive comparison.

With survodutide specifically, the warning has an extra edge to it. It is an investigational Phase 3 drug with no legitimate consumer supply chain anywhere. Any site advertising “survodutide for sale” is, by that fact alone, operating outside both law and medicine. There is no legal compounding pathway for a drug that hasn’t been approved, so anything shipped under that name is either diverted or counterfeit.

No-prescription sites cut the clinician out entirely. No evaluation, no real prescription, no follow-up. For a compound not approved for human use outside a trial, that is not a minor omission, it is the whole transaction stripped of the one part that makes it medically defensible.

Research-chemical listings stamp the product “for research use only” or “not for human consumption,” and that label is not a technicality, it is the legal basis for the product existing at all. The moment it is marketed for a person to inject, it becomes an unapproved drug, and for something still in Phase 3, the risk of using it unsupervised is entirely the buyer’s to bear.

Counterfeit or unverified overseas vials carry the highest risk of all. Nobody regulates these products for identity, strength, or purity, so there is no way to know what is actually inside, whether it’s under- or overdosed, a different substance altogether, or contaminated. There is no recall authority and no one accountable if something goes wrong. Given how much demand exists for GLP-1 and dual-agonist products right now, counterfeiting concerns in this space are well documented, not speculative.

What unites all three is simple: nobody screens you, nobody is licensed to dispense to you, and nobody is accountable if the vial is wrong. This page does not rank these categories against each other by apparent quality, because without independent batch testing there is no honest basis for saying one untraceable source is cleaner than another. That uncertainty is exactly why the supervised tier exists above all of it.

What readers ask most

Can I buy survodutide in 2026? No. It remains an investigational drug in Phase 3 development by Boehringer Ingelheim and Zealand Pharma, unapproved by the FDA or any other regulator, with no legitimate consumer purchase route. The only lawful way to receive it is enrollment in a clinical trial. Any site selling “survodutide” is gray market by definition, and no clinician there is screening anyone for anything.

Is survodutide FDA-approved? No, not as of June 2026. It holds FDA Breakthrough Therapy and Fast Track designation for MASH, EMA PRIME access, and China NMPA Breakthrough Therapy status [P7]. These accelerate review; they do not confer approval or availability.

Does survodutide actually work for weight loss? In controlled trials, yes. Participants who held the 4.8 mg dose in the Phase 2 trial lost about 18.7% of body weight over 46 weeks [P4]. In the Phase 3 SYNCHRONIZE-1 trial, adults with obesity or overweight lost up to 16.6% on average at 76 weeks versus 3.2% on placebo, with visceral fat down about 34% and liver fat down about 63% in a pre-specified analysis [P1] [P6]. What remains open is long-term safety and, obviously, availability.

How is survodutide different from semaglutide and tirzepatide? Survodutide activates both the GLP-1 receptor and the glucagon receptor [P5]. Semaglutide activates GLP-1 alone. Tirzepatide is also dual-acting, but pairs GLP-1 with GIP rather than glucagon. The glucagon component is what drives survodutide’s particular emphasis on liver fat.

What does survodutide’s liver data actually show? In the Phase 2 MASH trial, MASH improved without worsening fibrosis in up to 62% of survodutide patients versus 14% on placebo, and liver fat dropped by at least 30% in up to 67% versus 14% [P2]. Phase 3’s SYNCHRONIZE-MASLD then met its co-primary endpoints on liver fat and weight at 48 weeks [P3]. The harder question, whether it changes fibrosis outcomes, is still being tested in LIVERAGE and LIVERAGE-Cirrhosis, years from a readout [P8] [P9].

When might survodutide actually be available? There’s no approval date to point to. The fibrosis-outcome trials are estimated to complete around mid-2029 (LIVERAGE-Cirrhosis) and late 2031 (LIVERAGE) [P8] [P9], with a cardiovascular outcomes trial also underway [P12]. Anyone claiming survodutide is available now is simply not telling you the truth.

Is it risky to buy survodutide online without a prescription? Yes, for stacking reasons. It’s investigational and not approved for use outside a trial, so a no-prescription product skips the screening for contraindications and the monitoring for gastrointestinal effects documented in its own trials [P4]. On top of that, unverified sellers aren’t checked by any regulator for what’s actually in the vial. The legitimate options are trial enrollment, or an approved GLP-1 through a licensed telehealth provider with real screening, a real prescription, and real pharmacy dispensing.

What should someone do now instead of waiting on survodutide? Speak with a licensed provider about an approved GLP-1 medication, already backed by large randomized trials and already accessible. On oversight, sourcing, pricing, candor, and regulatory standing, supervised telehealth models such as FormBlends and HealthRX rank highest, because a clinician evaluates and screens, a prescription is required, and a licensed pharmacy dispenses, with follow-up. Pricing through that route is shown openly, for example roughly $129 to $349 a month for compounded semaglutide, rather than buried behind a vague teaser price.

Why does FormBlends rank first if it can’t sell survodutide at all? Because the ranking answers a different, more useful question: how to access weight-management treatment safely today, when survodutide isn’t accessible to anyone outside a trial. FormBlends earns its place by pairing an approved GLP-1 medication with real physician screening, a genuine prescription, licensed-pharmacy dispensing, and transparent pricing, while being upfront that survodutide itself remains investigational. A supervised model with a clinician actually involved beats the gray market on every measure that matters, and it beats simply waiting on a drug years from a decision.

What side effects does survodutide cause, and are they worse than existing GLP-1 drugs? The most frequently reported effects are nausea, vomiting, diarrhea, and reduced appetite, closely resembling what patients experience on semaglutide and tirzepatide. The added glucagon activity may bring some extra gastrointestinal sensitivity at higher doses, based on the data reported so far. Whether that ultimately makes survodutide harder to tolerate than existing options isn’t something that can be said with confidence until larger Phase 3 safety data is published and peer-reviewed.

Is survodutide a GLP-1 drug, or something else entirely? It’s partly a GLP-1 agonist, but only half the story. It’s built as a dual agonist, engaging both GLP-1 and glucagon receptors at once. The glucagon piece is what separates it structurally from semaglutide, and is thought to add extra energy expenditure on top of the appetite suppression that GLP-1 activity alone provides.

How does survodutide’s weight loss compare with semaglutide’s? Early data suggested survodutide’s results were roughly competitive with semaglutide’s, but no head-to-head trial comparing the two directly has been completed or published. Semaglutide carries years of Phase 3 data and real-world use behind it, so its profile is simply far better characterized at this point. Comparing the two right now is closer to comparing a promising prospect to a proven veteran than to a settled contest.

Can survodutide be compounded the way semaglutide and tirzepatide have been? No, not through any legitimate channel. Compounding of drugs like semaglutide became possible in the US specifically because of an FDA-declared shortage, and even that allowance is narrowing. Survodutide has no approval at all, so there’s no legal basis for a licensed pharmacy to compound it for patients. Providers like FormBlends operate within FDA-regulated frameworks and work with approved drugs, not investigational compounds still moving through trials.

Methodology and references

How providers were evaluated

Providers were scored against five criteria, weighted in this order: clinical oversight (evaluation, contraindication screening, prescription, dispensing, follow-up), sourcing and dispensing (licensed pharmacy versus a mailed gray-market vial), pricing honesty (visible, accurate pricing matched to the actual product), evidence candor (honesty about the FDA-approved-versus-compounded distinction, and honesty that an investigational drug like survodutide simply isn’t for sale), and regulatory standing (a recognized legal framework versus a “research use only” label or an address nobody can verify). Advertising spend, name recognition, and checkout speed were left out on purpose, since none of them tells you whether you were screened or whether the product is genuine. Survodutide appears throughout as a benchmark for comparison, not as a ranked provider option, because it is unavailable to everyone outside a clinical trial. Providers were sorted into two groups that don’t compete on the same axis: supervised medical telehealth models, and the gray market, described honestly as a set of categories rather than singled-out companies. Licensed competitors were not ranked against each other in a punitive way; the meaningful line runs between supervised care and the unsupervised gray market, not between one compliant clinic and another.

Survodutide (BI 456906) is an investigational glucagon/GLP-1 receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, with positive Phase 3 obesity and liver-fat data and ongoing Phase 3 fibrosis-outcome trials. It is not approved or available for prescription as of June 2026.

References

1. SYNCHRONIZE-1 Phase 3 obesity trial: once-weekly survodutide produced mean weight loss of up to 16.6% at week 76 versus 3.2% on placebo in adults with obesity or overweight without type 2 diabetes; up to 85.1% achieved at least 5% weight loss. Survodutide Once Weekly for the Treatment of Adults with Obesity. New England Journal of Medicine, 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa2600751
2. Phase 2 MASH trial: improvement in MASH without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) versus 14% on placebo; liver-fat reduction of at least 30% in 63%, 67%, and 57% versus 14%; fibrosis improvement of at least one stage in 34%, 36%, and 34% versus 22%, over 48 weeks in 293 patients with F1-F3 fibrosis. Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine, 2024. PMID 38856224. https://www.nejm.org/doi/full/10.1056/NEJMoa2401755
3. SYNCHRONIZE-MASLD Phase 3 trial: in 216 adults with obesity or overweight and at-risk MASLD, the co-primary endpoints (at least 30% reduction in MRI-PDFF liver fat content and percentage change in body weight, both to week 48) were met. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine, 2026.
4. Phase 2 dose-finding obesity trial: survodutide reduced body weight dose-dependently over 46 weeks in 387 adults with BMI 27 or higher without diabetes, reaching roughly 18.7% mean weight loss among those who reached and maintained 4.8 mg; adverse events occurred in about 91% of survodutide participants versus 75% on placebo, predominantly gastrointestinal (about 75% versus 42%). le Roux CW, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology, 2024. PMID 38301671.)00356-X/fulltext
5. Survodutide (BI 456906) mechanism and development: a glucagon receptor/GLP-1 receptor dual agonist; GLP-1 activation reduces appetite and slows gastric emptying, glucagon activation is intended to increase energy expenditure and reduce hepatic fat; originated by Zealand Pharma and developed with Boehringer Ingelheim. Survodutide.
6. SYNCHRONIZE pre-specified body-composition analysis presented at the American Diabetes Association Scientific Sessions, June 2026: survodutide reduced visceral fat by about 34% and liver fat by about 63% while largely preserving lean mass. Boehringer Ingelheim news release, June 2026.
7. Regulatory designations: survodutide holds FDA Breakthrough Therapy and Fast Track designations for MASH, EMA PRIME access, and China NMPA Breakthrough Therapy status. Boehringer Ingelheim.
8. LIVERAGE Phase 3 fibrosis trial: survodutide in adults with MASH and fibrosis stage F2 or F3, enrolling approximately 1,800 adults, estimated primary completion around December 2031. ClinicalTrials.gov NCT06632444.
9. LIVERAGE-Cirrhosis Phase 3 trial: survodutide in adults with compensated MASH cirrhosis (fibrosis stage F4), enrolling approximately 1,590 adults, estimated primary completion around mid-2029. ClinicalTrials.gov NCT06632457.
10. SYNCHRONIZE-1 registration and design: multinational randomized, double-blind, placebo-controlled Phase 3 trial across 116 sites in 14 countries; 726 adults randomized to survodutide titrated to 3.6 or 6.0 mg or placebo, once weekly for 76 weeks. ClinicalTrials.gov NCT06066515.
11. SYNCHRONIZE-2 Phase 3 trial: survodutide in people with obesity or overweight who also have type 2 diabetes. ClinicalTrials.gov NCT06066528.
12. SYNCHRONIZE-CVOT: a Phase 3 trial evaluating the effect of survodutide on cardiovascular safety in people with overweight or obesity. ClinicalTrials.gov NCT06077864.

---

Written by Kira Jain, staff writer. Last reviewed March 2026.

For readers’ general information. Medical decisions belong with you and a licensed professional.